On March 25, 2025, Humacyte, Inc. entered into an underwriting agreement for an offering of 25 million shares at $2.00 each, expecting to raise approximately $46.6 million, or $53.7 million if an additional option is exercised. The offering is set to close on March 27, 2025, pending customary conditions.